[1]
|
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid":epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States[J]. J Clin Oncol, 2008, 26:3063-3072. doi: 10.1200/JCO.2007.15.4377 |
[2]
|
Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs):incidence, prognosis and recent trend toward improved survival[J]. Ann Oncol, 2008, 19:1727-1733. doi: 10.1093/annonc/mdn351 |
[3]
|
Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs):results from the National Cancer Registry of Spain(RGETNE)[J]. Ann Oncol, 2010, 21:1794-1803. doi: 10.1093/annonc/mdq022 |
[4]
|
Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancrea-tic neuroendocrine tumors[J]. Am J Surg Pathol, 2012, 36:173-184. doi: 10.1097/PAS.0b013e3182417d36 |
[5]
|
Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543:65-71. doi: 10.1038/nature21063 |
[6]
|
Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331:1199-1203. doi: 10.1126/science.1200609 |
[7]
|
Hong X, Qiao S, Li F, et al. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours:leading to a new classification system[J]. Gut, 2020, 69:877-887. doi: 10.1136/gutjnl-2018-317233 |
[8]
|
Chan CS, Laddha SV, Lewis PW, et al. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup[J]. Nat Commun, 2018, 9:4158. doi: 10.1038/s41467-018-06498-2 |
[9]
|
Xiao Y, Yang Y, Wang Y, et al. Five Novel Genes Related to the Pathogenesis and Progression of Pancreatic Neuroendocrine Tumors by Bioinformatics Analysis With RT-qPCR Verification[J]. Front Neurosci, 2019, 13:937. doi: 10.3389/fnins.2019.00937 |
[10]
|
Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions[J]. Cell, 2010, 140:678-691. doi: 10.1016/j.cell.2010.01.003 |
[11]
|
Elsasser SJ, Allis CD, Lewis PW. Cancer. New epigenetic drivers of cancers[J]. Science, 2011, 331:1145-1146. doi: 10.1126/science.1203280 |
[12]
|
Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors[J]. Gastroenterology, 2014, 146:453-460.e5. doi: 10.1053/j.gastro.2013.10.020 |
[13]
|
Singhi AD, Liu TC, Roncaioli JL, et al. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors[J]. Clin Cancer Res, 2017, 23:600-609. doi: 10.1158/1078-0432.CCR-16-1113 |
[14]
|
Kim JY, Brosnan-Cashman JA, An S, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival[J]. Clin Cancer Res, 2017, 23:1598-1606. doi: 10.1158/1078-0432.CCR-16-1147 |
[15]
|
Roy S, LaFramboise WA, Liu TC, et al. Loss of Chromatin-Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times[J]. Gastroenterology, 2018, 154:2060-2063.e8. doi: 10.1053/j.gastro.2018.02.026 |
[16]
|
Pea A, Yu J, Marchionni L, et al. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases[J]. Ann Surg, 2020, 271:566-573. doi: 10.1097/SLA.0000000000003022 |
[17]
|
Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarci-noma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes[J]. Nat Genet, 2012, 44:570-574. doi: 10.1038/ng.2246 |
[18]
|
Wang SC, Nassour I, Xiao S, et al. SWI/SNF component ARID1A restrains pancreatic neoplasia formation[J]. Gut, 2019, 68:1259-1270. doi: 10.1136/gutjnl-2017-315490 |
[19]
|
Zhang L, Jia CW, Lu ZH, et al. ARID1A expression of SWI/SNF remodeling complex in pancreatic neuroendocrine tumor[J]. Zhonghua Bing Li Xue Za Zhi, 2016, 45:571-574. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhblx201608015 |
[20]
|
Han X, Chen W, Chen P, et al. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors[J]. Pancreas, 2020, 49:514-523. doi: 10.1097/MPA.0000000000001535 |
[21]
|
Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1(MEN1)[J]. J Clin Endocrinol Metab, 2012, 97:2990-3011. doi: 10.1210/jc.2012-1230 |
[22]
|
Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma[J]. Science, 2011, 331:43. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d2be181d4234d0d4c3651064f1dd466d |
[23]
|
吴婷, 黄小花. MENl胰岛素瘤中细胞周期蛋白cyclin B2高表达的作用[J].生理学报, 2011, 63:555-564. |
[24]
|
Gurung B, Feng Z, Iwamoto DV, et al. Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome[J]. Cancer Res, 2013, 73:2650-2658. doi: 10.1158/0008-5472.CAN-12-3158 |
[25]
|
Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer[J]. Nat Rev Cancer, 2006, 6:846-856. doi: 10.1038/nrc1991 |
[26]
|
Thiel AT, Blessington P, Zou T, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele[J]. Cancer Cell, 2010, 17:148-159. doi: 10.1016/j.ccr.2009.12.034 |
[27]
|
Feng Z, Wang L, Sun Y, et al. Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase[J]. Cancer research, 2017, 77:401-411. doi: 10.1158/0008-5472.CAN-16-1567 |
[28]
|
Vandamme T, Beyens M, Boons G, et al. Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms[J]. Endocr Relat Cancer, 2019, 26:1-12. |
[29]
|
Dumanski JP, Rasi C, Bjorklund P, et al. A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors[J]. Endocr Relat Cancer, 2017, 24:427-443. doi: 10.1530/ERC-17-0196 |
[30]
|
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy[J]. J Clin Oncol, 2009, 27:2278-2287. doi: 10.1200/JCO.2008.20.0766 |
[31]
|
Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN[J]. Proc Natl Acad Sci U S A, 2003, 100:7491-7496. doi: 10.1073/pnas.0932835100 |
[32]
|
Han X, Ji Y, Zhao J, et al. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors[J]. Tumour Biol, 2013, 34:2871-2879. doi: 10.1007/s13277-013-0849-1 |
[33]
|
Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome(RADIANT-2):a randomised, placebo-control-led, phase 3 study[J]. Lancet, 2011, 378:2005-2012. doi: 10.1016/S0140-6736(11)61742-X |
[34]
|
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364:514-523. doi: 10.1056/NEJMoa1009290 |
[35]
|
Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents[J]. Ann Oncol, 2006, 17:1733-1742. doi: 10.1093/annonc/mdl105 |
[36]
|
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors:a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27:4656-4663. doi: 10.1200/JCO.2009.22.8510 |
[37]
|
Caplin ME, Pavel M, Cwikla JB, et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours:the CLARINET open-label extension study[J]. Endocr Relat Cancer, 2016, 23:191-199. doi: 10.1530/ERC-15-0490 |
[38]
|
Cao Y, Gao Z, Li L, et al. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1[J]. Nat Commun, 2013, 4:2810. doi: 10.1038/ncomms3810 |